Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy

This publication has 28 references indexed in Scilit:

• Safety and Immunogenicity of a Heptavalent Pneumococcal Conjugate Vaccine in Infants With Human Immunodeficiency Virus Type 1 Infection
  Pediatrics, 2003
• Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness
  AIDS, 2002
• Epidemiology of Invasive Streptococcus pneumoniae Infections in the United States, 1995-1998Opportunities for Prevention in the Conjugate Vaccine Era
  JAMA, 2001
• Increasing Prevalence of Multidrug-ResistantStreptococcus pneumoniaein the United States
  New England Journal of Medicine, 2000
• Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis
  Pediatrics, 2000
• Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis
  Pediatrics, 2000
• 23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial
  The Lancet, 2000
• Safety and Immunogenicity of Three Doses of a Five-Valent Pneumococcal Conjugate Vaccine in Children Younger Than Two Years With and Without Human Immunodeficiency Virus Infection
  Pediatrics, 1997
• Invasive Pneumococcal Infections in Human Immunodeficiency Virus-Infected Children
  The Journal of Infectious Diseases, 1996
• Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine
  The Journal of Pediatrics, 1994